The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?
Authors
Keywords
-
Journal
American Journal of Cardiovascular Drugs
Volume 23, Issue 6, Pages 601-608
Publisher
Springer Science and Business Media LLC
Online
2023-09-08
DOI
10.1007/s40256-023-00610-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dipeptidyl peptidase 4 inhibition rescues PKA-eNOS signaling and suppresses aortic hypercontractility in male rats with heart failure
- (2023) Milene T. Fontes et al. LIFE SCIENCES
- Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
- (2023) Juthi Adhikari et al. Journal of Diabetes Investigation
- Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
- (2023) Deborah J. Wexler et al. JAMA Internal Medicine
- GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use
- (2023) Konstantinos Arvanitakis et al. Current Obesity Reports
- Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review
- (2023) Akira Mima et al. BIOMEDICINE & PHARMACOTHERAPY
- Tirzepatide and potential use for metabolically healthy obesity
- (2023) Sidar Copur et al. European Journal of Internal Medicine
- Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-Based Cohort Study
- (2022) Eugene Han et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mitochondria-targeted drugs for diabetic kidney disease
- (2022) Akira Mima Heliyon
- A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease
- (2022) Theocharis Koufakis et al. American Journal of Cardiovascular Drugs
- The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
- (2022) Dario Giugliano et al. Cardiovascular Diabetology
- Fear of hypoglycemia—An underestimated problem
- (2022) Agnieszka Przezak et al. Brain and Behavior
- A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches
- (2022) Akira Mima ADVANCES IN THERAPY
- Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
- (2022) Meir Schechter et al. Cardiovascular Diabetology
- The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
- (2022) Konstantinos Arvanitakis et al. PHARMACOLOGICAL RESEARCH
- Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials
- (2022) Liyun He et al. BMJ-British Medical Journal
- First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
- (2022) Jin G. Choi et al. ANNALS OF INTERNAL MEDICINE
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETES CARE
- Toward a new model for the management of type 2 diabetes: The mountain is there and there is no other option than to climb it
- (2022) Theocharis Koufakis et al. PHARMACOLOGICAL RESEARCH
- Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
- (2022) Yi-Hong Zeng et al. Scientific Reports
- How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
- (2022) Konstantinos Arvanitakis et al. Cancers
- Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
- (2021) Avivit Cahn et al. DIABETES CARE
- Urinary dipeptidyl peptidase‐4 protein is increased by linagliptin and is a potential predictive marker of urine albumin‐to‐creatinine ratio reduction in patients with type 2 diabetes
- (2021) Thomas Klein et al. DIABETES OBESITY & METABOLISM
- The influence of hypoglycemia on the specific quality of life in type 2 diabetes mellitus: a comparative cross-sectional study of diabetics with and without hypoglycemia in Xi’an, China
- (2021) Chao Wu et al. Health and Quality of Life Outcomes
- Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?
- (2021) Theocharis Koufakis et al. Expert Review of Clinical Pharmacology
- Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2021) Leila Janani et al. Drug Research
- A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN
- (2020) Mohamed Hassanein et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes
- (2020) Akira Mima et al. Scientific Reports
- A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?
- (2020) Theocharis Koufakis et al. Journal of Diabetes
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
- (2020) Apostolos Tsapas et al. ANNALS OF INTERNAL MEDICINE
- Severe Hypoglycemia and Risk of Falls in Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
- (2020) Alexandra K. Lee et al. DIABETES CARE
- Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
- (2020) Ayano Kubo et al. BMC Nephrology
- Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
- (2020) David Matthews et al. Diabetes Therapy
- Treating latent autoimmune diabetes in adults in the era of cardiovascular outcomes trials: Old dog should learn new tricks
- (2020) Theocharis Koufakis et al. DIABETIC MEDICINE
- Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies
- (2020) Theocharis Koufakis et al. MATURITAS
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
- (2019) Binayak Sinha et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Clinical Use of DPP-4 Inhibitors
- (2019) Baptist Gallwitz Frontiers in Endocrinology
- Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study
- (2019) Jae-Seung Yun et al. Cardiovascular Diabetology
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
- (2019) David R Matthews et al. LANCET
- Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all
- (2019) Theocharis Koufakis et al. Journal of Diabetes
- Economic burden of hypoglycemia for type II diabetes mellitus patients in Malaysia
- (2019) Syed Mohamed Aljunid et al. PLoS One
- Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis
- (2019) Subin Lee et al. Scientific Reports
- Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy
- (2018) John M. Dennis et al. DIABETES CARE
- Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
- (2018) Se Hee Min et al. Scientific Reports
- Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
- (2018) Lana C. Pinto et al. Scientific Reports
- Obesity-associated glomerular inflammation increases albuminuria without renal histological changes
- (2018) Akira Mima et al. FEBS Open Bio
- The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (the Diabetes & Aging Study)
- (2018) Neda Laiteerapong et al. DIABETES CARE
- Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects
- (2017) Huaiqing Wang et al. Journal of Diabetes
- Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
- (2016) Jan W. Eriksson et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism
- (2016) Bo Ahrén et al. DIABETOLOGIA
- Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
- (2016) Akira Mima Journal of Diabetes Research
- The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial
- (2015) J.-B. Zhou et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial
- (2013) Michael E. Miller et al. DIABETES CARE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets
- (2013) Akira Mima Journal of Diabetes Research
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC Activation in Diabetes
- (2012) A. Mima et al. DIABETES
- Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
- (2012) K. Gooßen et al. DIABETES OBESITY & METABOLISM
- Implications of Treatment That Target Protective Mechanisms Against Diabetic Nephropathy
- (2012) Akira Mima et al. SEMINARS IN NEPHROLOGY
- Severe Hypoglycemia and Risks of Vascular Events and Death
- (2010) Sophia Zoungas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication
- (2010) Marco DiBonaventura et al. Patient Preference and Adherence
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation